Search Results - "Meriggioli, Matthew N."

Muscle autoantibodies in myasthenia gravis: beyond diagnosis? by Meriggioli, Matthew N, Sanders, Donald B

“…Myasthenia gravis is an autoimmune disorder of the neuromuscular junction. A number of molecules, including ion channels and other proteins at the…”
Get more information

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity by Meriggioli, Matthew N, MD, Sanders, Donald B, MD

“…Summary Acquired myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction in which patients experience fluctuating skeletal muscle…”
Get full text

Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis by Thiruppathi, Muthusamy, Sheng, Jian Rong, Li, Liangcheng, Prabhakar, Bellur S, Meriggioli, Matthew N

“…Abstract Myasthenia gravis (MG) is an autoimmune disorder caused by target-specific pathogenic antibodies directed toward postsynaptic neuromuscular junction…”
Get full text

Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease by Rowin, Julie, Cheng, Grace, Lewis, Steven L., Meriggioli, Matthew N.

“…We present three cases of dropped head syndrome that occurred as a complication of mantle field (i.e., lymph nodes of the neck, axillae, and mediastinum) or…”
Get full text

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy by Mendell, Jerry R, Al-Zaidy, Samiah A, Lehman, Kelly J, McColly, Markus, Lowes, Linda P, Alfano, Lindsay N, Reash, Natalie F, Iammarino, Megan A, Church, Kathleen R, Kleyn, Aaron, Meriggioli, Matthew N, Shell, Richard

“…This ongoing study assesses long-term safety and durability of response in infants with spinal muscular atrophy (SMA) type 1 after dosing with onasemnogene…”
Get more information

Novel and recurrent EMD mutations in patients with Emery-Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot by Brown, Charlotte A, Scharner, Juergen, Felice, Kevin, Meriggioli, Matthew N, Tarnopolsky, Mark, Bower, Matthew, Zammit, Peter S, Mendell, Jerry R, Ellis, Juliet A

“…Emery-Dreifuss muscular dystrophy (EDMD) is a neuromuscular disorder exhibiting a cardiomyopathy with cardiac conduction defects. X-linked EDMD arises from…”
Get full text

The Clinical Spectrum of Necrotizing Autoimmune Myopathy: A Mixed Bag With Blurred Lines by Meriggioli, Matthew N

Get more information

Prospect for Pharmacological Therapies to Treat Skeletal Muscle Dysfunction by Meriggioli, Matthew N., Roubenoff, Ronenn

“…Skeletal muscle weakness is a leading cause of mobility disability in the elderly (sarcopenia), as a complication of acute or chronic illness (cachexia), and…”
Get full text

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis by Guptill, Jeffrey T., Soni, Madhu, Meriggioli, Matthew N.

“…Myasthenia gravis (MG) is an autoimmune disease associated with the production of autoantibodies against 1) the skeletal muscle acetylcholine receptor; 2)…”
Get full text

Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis by Thiruppathi, Muthusamy, Rowin, Julie, Ganesh, Balaji, Sheng, Jian Rong, Prabhakar, Bellur S, Meriggioli, Matthew N

“…Previous studies have reported alterations in numbers or function of regulatory T (Treg) cells in myasthenia gravis (MG) patients, but published results have…”
Get full text

Functional defect in regulatory T cells in myasthenia gravis by Thiruppathi, Muthusamy, Rowin, Julie, Li Jiang, Qin, Sheng, Jian Rong, Prabhakar, Bellur S., Meriggioli, Matthew N.

“…Forkhead box P3 (FOXP3) is a transcription factor necessary for the function of regulatory T cells (Treg cells). Treg cells maintain immune homeostasis and…”
Get full text

Recommendations for myasthenia gravis clinical trials by Benatar, Michael, Sanders, Donald B., Burns, Ted M., Cutter, Gary R., Guptill, Jeffrey T., Baggi, Fulvio, Kaminski, Henry J., Mantegazza, Renato, Meriggioli, Matthew N., Quan, Joanne, Wolfe, Gil I.

“…The recommendations for clinical research standards published in 2000 by a task force of the Medical Scientific Advisory Board (MSAB) of the Myasthenia Gravis…”
Get full text

Granulocyte macrophage colony‐stimulating factor treatment of a patient in myasthenic crisis: Effects on regulatory T cells by Rowin, Julie, Thiruppathi, Muthusamy, Arhebamen, Ebinehita, Sheng, Jianrong, Prabhakar, Bellur S., Meriggioli, Matthew N.

“…Introduction: In this study we describe a patient with a prolonged myasthenic crisis refractory to conventional immunomodulatory therapy who was treated with…”
Get full text

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study by GomezMancilla, Baltazar, Meriggioli, Matthew N, Genge, Angela, Roubenoff, Ronenn, Espié, Pascal, Dupuy, Cyrielle, Hartmann, Nicole, Pezous, Nicole, Kinhikar, Arvind, Tichy, Mia, Dionne, Annie, Vissing, John, Andersen, Henning, Schoser, Benedikt, Meisel, Andreas, Jordan, Berit, Devlikamova, Farida, Poverennova, Irina, Stuchevskaya, Fatima, Lin, Thy-Sheng, Rush, James S, Gergely, Peter

“…Increased morbidity in many patients with myasthenia gravis (MG) on long-term immunosuppression highlights the need for improved treatments. The aim of this…”
Get full text

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial by Grunseich, Christopher, Miller, Ram, Swan, Therese, Glass, David J, El Mouelhi, Mohamed, Fornaro, Mara, Petricoul, Olivier, Vostiar, Igor, Roubenoff, Ronenn, Meriggioli, Matthew N, Kokkinis, Angela, Guber, Robert D, Budron, Maher S, Vissing, John, Soraru, Gianni, Mozaffar, Tahseen, Ludolph, Albert, Kissel, John T, Fischbeck, Kenneth H, Grunseich, Christopher, Miller, Ram, Swan, Therese, Glass, David J, Mouelhi, Mohamed El, Fornaro, Mara, Petricoul, Olivier, Vostiar, Igor, Roubenoff, Ronenn, Meriggioli, Matthew N, Dahlqvist, Julia, Witting, Nanna, Vissing, John, Martinelli, Ilaria, Querin, Giorgia, Soraru, Gianni, Goyal, Namita A, Cash, Tiyonnoh M, Minton, Brian, Mozaffar, Tahseen, Rosenbohm, Angela, Weiland, Ulrike, Weydt, Patrick, Ludolph, Albert, Chelnick, Sharon, Iyadurai, Stanley, King, Wendy, Kissel, John T, Budron, Maher S, Guber, Robert D, Kokkinis, Angela, Fischbeck, Kenneth H

“…Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease caused by CAG repeat expansion in the androgen receptor gene. Patients with this…”
Get full text

TDP-43 Proteinopathy: Aggregation and Propagation in the Pathogenesis of Amyotrophic Lateral Sclerosis by Meriggioli, Matthew N., Kordower, Jeffrey H.

Get full text

GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis by Sheng, Jian Rong, Muthusamy, Thiruppathi, Prabhakar, Bellur S, Meriggioli, Matthew N

“…Abstract We and others have demonstrated the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) to suppress autoimmunity by increasing the…”
Get full text

Fatigue and abnormal neuromuscular transmission in Kennedy's disease by Meriggioli, Matthew N., Rowin, Julie

“…We describe a patient with Kennedy's disease (X‐linked bulbospinal neuronopathy) who experienced leg muscle fatigue with long‐distance running. The patient…”
Get full text

Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations by Scharner, Juergen, Brown, Charlotte A, Bower, Matthew, Iannaccone, Susan T, Khatri, Ismail A, Escolar, Diana, Gordon, Erynn, Felice, Kevin, Crowe, Carol A, Grosmann, Carla, Meriggioli, Matthew N, Asamoah, Alexander, Gordon, Ora, Gnocchi, Viola F, Ellis, Juliet A, Mendell, Jerry R, Zammit, Peter S

“…Mutations in LMNA cause a variety of diseases affecting striated muscle including autosomal Emery-Dreifuss muscular dystrophy (EDMD), LMNA-associated…”
Get full text

Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells by Sheng, Jian Rong, Li, Liangcheng, Ganesh, Balaji B, Vasu, Chenthamarakshan, Prabhakar, Bellur S, Meriggioli, Matthew N

“…Dendritic cells (DCs) have the potential to activate or tolerize T cells in an Ag-specific manner. Although the precise mechanism that determines whether DCs…”
Get full text